India, Developing Nations To Press Third-World Disease Drugs At WHO Meeting (India)
This article was originally published in PharmAsia News
India and other developing nations plan to make a strong case in an April international lobbying effort for funding drugs aimed at some of the diseases plaguing their segment of the world. Diseases in the developing world, such as tuberculosis and malaria, comprise less than 10 percent of research dollars spent on drug research even though those diseases account for more than 90 percent of the diseases afflicting the world's population. The World Health Organization's decision-making body has scheduled international negotiations in Switzerland in April to hear from participating nations on the issue. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.